Key result
RSV vaccine efficacy for preventing heart failure hospitalizations awaits clinical results from the extended DAN-RSV trial.
Why the study?
Does RSV vaccine prevent respiratory and cardiovascular hospitalizations in patients with heart failure?
Does RSV vaccine prevent respiratory and cardiovascular hospitalizations in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patients may present with signs and symptoms of viral pneumonia but commonly present with decompensated heart failure or COPD exacerbations, with RSV as the inciting event leading to worsening of their underlying disease.”
“For isolated cardiovascular events, no statistically significant between-group differences were observed. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization.”
“Together, these data provide real-world evidence to support RSV vaccination, while highlighting the need to better define re-vaccination schedules.”
Investigates respiratory and cardiovascular hospitalizations in patients with heart failure, highlighting potential cardiopulmonary protection from vaccination.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Skaarup et al. (2026) studied this question. RSV vaccine efficacy for preventing hospitalizations in heart failure is evaluated in the extended DAN-RSV trial, though the abstract lacks clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: